Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Human Apotransferrin in Patients With β-thalassemia Intermedia

NCT03993613 is registered in ClinicalTrials.gov with Prothya Biosolutions as lead sponsor.

NCT NCT03993613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03993613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Human Apotransferrin in Patients With β-thalassemia Intermedia
Lead sponsor
Prothya Biosolutions
Phase
Phase 2
Overall status
Terminated
Start date
March 21, 2019
Completion date
March 31, 2022
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

β-thalassemia intermedia